Zhang Xuqing, Li Xiaojie, Allan George F, Sbriscia Tifanie, Linton Olivia, Lundeen Scott G, Sui Zhihua
Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, LLC, 665 Stockton Drive, Exton, PA 19341, USA.
J Med Chem. 2007 Aug 9;50(16):3857-69. doi: 10.1021/jm0613976. Epub 2007 Jul 18.
A novel series of pyrazolines 2 have been designed, synthesized, and evaluated by in vivo screening as tissue-selective androgen receptor modulators (SARMs). Structure-activity relationships (SAR) were investigated at the R1 to R6 positions as well as the core pyrazoline ring and the anilide linker. Overall, strong electron-withdrawing groups at the R1 and R2 positions and a small group at the R5 and R6 position are optimal for AR agonist activity. The (S)-isomer of 7c exhibits more potent AR agonist activity than the corresponding (R)-isomer. (S)-7c exhibited an overall partial androgenic effect but full anabolic effect via oral administration in castrated rats. It demonstrated a noticeable antiandrogenic effect on prostate in intact rats with endogenous testosterone. Thus, (S)-7c is a tissue-selective nonsteroidal androgen receptor modulator with agonist activity on muscle and mixed agonist and antagonist activity on prostate.
设计、合成了一系列新型吡唑啉2,并通过体内筛选对其作为组织选择性雄激素受体调节剂(SARM)进行了评估。研究了R1至R6位以及核心吡唑啉环和酰苯胺连接基的构效关系(SAR)。总体而言,R1和R2位的强吸电子基团以及R5和R6位的小基团对AR激动剂活性最为有利。7c的(S)-异构体比相应的(R)-异构体表现出更强的AR激动剂活性。(S)-7c经口服给药对去势大鼠表现出总体部分雄激素作用但完全合成代谢作用。在具有内源性睾酮的完整大鼠中,它对前列腺表现出明显的抗雄激素作用。因此,(S)-7c是一种组织选择性非甾体雄激素受体调节剂,对肌肉具有激动剂活性,对前列腺具有混合激动剂和拮抗剂活性。